What is the main business of Agene?

The main business activity of Agene focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on January 4, 2017.

Where is the headquarters located?

The headquarters is located at: ul. Pokoju 49B, 71-739 Szczecin.

Who is on the management board?

The management board consists of: Andrzej Dybus (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

The company reported a revenue of $19,397 in 2025, which is a decrease of 29.5% compared to 2024.

Is the company profitable?

No, the company recorded a net loss of $4,985 in 2025. For comparison, in 2024 the loss was $3,852, meaning the company increased its loss by 29.1%.

What is the largest operating cost?

The largest operating cost category falls under materials and energy. This category amounted to $8,016 in 2025, representing 33% of all operating expenses.

Agenesp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2017-01-04

Share capital

5 000,00 PLN

Registered address

ul. Pokoju 49B, 71-739 Szczecin, Poland

Financials

Revenue history (in k)

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 56 days late).

202515/07/2026
202414/07/2025
202308/07/2024
202229/05/2023
202109/09/2022
202012/07/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 19.40kMedianUSD 55.35kAverageUSD 2.71m

Net profit

This companyUSD -4.98kMedianUSD -1.27kAverageUSD -92.09k

Operating costs

This companyUSD 24.09kMedianUSD 66.19kAverageUSD 2.67m

Assets

This companyUSD 7.41kMedianUSD 133.95kAverageUSD 3.03m

Industry

Research and experimental development on biotechnology (72.11.Z)Primary

Authorized Representatives

Andrzej Dybus – President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Andrzej Dybusage 54	99	$1,337.12	99%
Others	1	$13.51	1%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2017-05-11.

mBank
35 1140 2004 0000 3412 0612 4988
mBank
66 1140 2004 0000 3902 7663 4101

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Jun 9, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$1,282$1,282	Prezydent Miasta Szczecin

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
Read-GeneS.A.	$2,163,474.84	read-gene.com
Platforma Badań Genetycznychsp. z o.o.	$28,558.39	zdrowegeny.pl
Medtransfersp. z o.o.	$21,666.01	codete.com
Bioselsp. z o.o.	$19,100.32	selol.pl
InventroS.A.	$12,176.61	inventro.co
Detoxedsp. z o.o.	$11,972.37	detoxed.pl
ArthecS.A.	$10,911.16	arthec.eu
Vitagenumsp. z o.o.	$9,376.94	vitagenum.pl
4cell TherapiesS.A.	$9,123.06	4celltherapies.com
Poltisssp. z o.o.	$3,843.72	poltiss.com

Change history

Date	Event
2018-11-30	Address change (Ul. Santocka 19/126, 71-113, Szczecin → Ul. Pokoju 49b, 71-739, Szczecin)
2017-01-04	Entered in the register

FAQ

Last updated: 2026-07-16